A Phase II Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Rebif® in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

NCT00050778 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

334

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis, Relapsing-Remitting

Interventions

BIOLOGICAL: Interferon beta-1a
BIOLOGICAL: Alemtuzumab 12 mg
BIOLOGICAL: Alemtuzumab 24 mg

Sponsor

Genzyme, a Sanofi Company

Collaborators

[object Object]